	US 12,268,742 B2
	Nanotherapeutic systems and methods using particle-driven photodynamic therapy (PDT)
Michelle S. Bradbury, New York, NY (US); Ulrich Wiesner, Ithaca, NY (US); Snehal G. Patel, New York, NY (US); Feng Chen, New York, NY (US); Brian Madajewski, New York, NY (US); and Daniella Karassawa Zanoni, New York, NY (US)
Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US); and CORNELL UNIVERSITY, Ithaca, NY (US)
Appl. No. 17/051,928
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US); and Cornell University, Ithaca, NY (US)
PCT Filed Apr. 29, 2019, PCT No. PCT/US2019/029598 § 371(c)(1), (2) Date Oct. 30, 2020, PCT Pub. No. WO2019/212945, PCT Pub. Date Nov. 7, 2019.
Claims priority of provisional application 62/723,044, filed on Aug. 27, 2018.
Claims priority of provisional application 62/666,086, filed on May 2, 2018.
Prior Publication US 2021/0121569 A1, Apr. 29, 2021
Int. Cl. A61K 41/00 (2020.01); A61K 47/69 (2017.01); A61K 51/12 (2006.01)

CPC A61K 41/0057 (2013.01) [A61K 41/0052 (2013.01); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 51/1244 (2013.01)]

25 Claims

1. A nanotherapeutic method using particle-driven photodynamic therapy (PDT), the method comprising:

(a) administering to a tissue of a subject a first composition comprising nanoparticles, wherein the nanoparticles have an average diameter no greater than 20 nm,

wherein the nanoparticles comprise:

(i) a PDT-active moiety comprising a PDT-photosensitive agent within the nanoparticle, and

(b) directing excitation light onto the tissue of the subject to activate the PDT-active moiety; and